Could Sponsors’ Supply Chain Policing Have Caught Alleged CRO Fraud?
Executive Summary
The US FDA always encourages sponsors to ensure their suppliers and contractors are following the law, but agency inspectors may have been the only ones who could have discovered the data integrity problems that forced the downgrading of more than 100 generic drug applications.
You may also be interested in...
Califf Floats Third-Party Supply Chain Monitoring To Fight Product Shortages
The US FDA commissioner’s call for the agency or someone else to watch supply chains and anticipate problems sounds a lot like a generics industry idea from 2011.
Will US FDA Offer Regulatory Flexibility For ANDAs Downgraded Because Of CRO Investigation?
Complex generic may have some wiggle room, but the only choice for many sponsors may be to redo the affected studies or withdraw the products that have lost bioequivalence status after FDA questioned the integrity of the data from two contract researchers.
Robert Califf’s Chance To Make History At The US FDA
Robert Califf’s first tenure as US FDA Commissioner was decidedly anti-climactic. His return trip – assuming the Senate confirms him – will be potentially transformational: he will be the leader that defines what FDA is after COVID.